Repligen (RGEN) Reports Financials, Guidance for 2012

QualityStocks would like to highlight Repligen Corporation (NASDAQ: RGEN), a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology.

In the company’s news today,

Repligen posted financial results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

Total revenue for the fourth quarter of fiscal year 2011 was $5.9 million compared to $4.8 million reported for the same period in fiscal year 2010.

The company reported a net loss for the fourth quarter 2011 at $2.0 million, or $(0.06) per diluted share, compared to a net loss of $1.6 million, or $(0.05) per diluted share, in the same period in fiscal year 2010.

Total revenue for the fiscal full year 2011 increased 30 percent to $27.2 million compared to total revenue of $20.9 million for fiscal year 2010.

Repligen reported a net loss for the year at $44,000, or $0.00 per diluted share, compared to a net loss of $4.0 million, or $(0.13) per diluted share, in the prior year.

Cash and investments as of March 31, 2011, were $61.5 million compared to $59.1 million reported for the year ended March 31, 2010.

The company spent the last 12 months on business expansion and on preparing one of its drug candidates for a New Drug Application (NDA) with the U.S. Food and Drug Administration.

“During the past year, we advanced our product candidate RG1068 toward an NDA filing and expanded our bioprocessing business,” Walter C. Herlihy, president and CEO of Repligen stated in the press release. “We look forward to gaining marketing approval for RG1068 and pursuing the acquisition of additional assets to expand our revenue base.”

The company offered guidance for fiscal year 2012, which started on April 1, 2011, and will end on March 31, 2012, increasing its total revenue expectations to range between $29 million and $31 million.

Repligen expects a net loss for 2012 of approximately $3 million and a cash burn of approximately $2 million.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.